Stocks
Enliven Therapeutics, Inc.ELVN
NASDAQHealthcareBiotechnology$41.52
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing precision therapies for cancer, with a focus on kinase inhibitors targeting specific genetic alterations. Its lead programs are designed for patients with chronic myeloid leukemia and other solid tumors, and the company is advancing multiple candidates through early-stage trials. Investors track ELVN for its pipeline progress and potential in targeted oncology.
52W Range: $14.79-$62.32
Congressional Interest in Enliven Therapeutics, Inc. (ELVN)
No congressional trades have been disclosed for Enliven Therapeutics, Inc. (ELVN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ELVN?
No congressional trades found for this stock.